Elsevier MDL and TEMIS provide a unique, innovative chemical information solution

Elsevier MDL expertise in chemistry combined with TEMIS text-mining products enable pharmaceutical and chemical corporations to mine business-critical information in chemical documents

San Leandro, CA and Paris, France, January 3, 2006 - Elsevier MDL, the pioneering company in discovery informatics, and TEMIS, the leading provider of Text Mining enterprise solutions, announced today that they have co-developed the Chemical Entity Relationship Skill Cartridge(tm), a new software application that identifies and extracts chemical information from text documents.

The software identifies chemical compound names, chemical classes and molecular formulae in text documents and translates extracted information into the chemist's language: the chemical structure.

Powerful features include:

The Chemical Entity Relationship Skill Cartridge(tm) integrates the Chemical Name Recognition software developed and used by Elsevier MDL to identify chemical names and extract reaction schemes from scientific literature and patents. This Chemical Name Recognition software has proven its robustness and high-quality extraction capabilities for more than two years in the production of the MDL® Patent Chemistry Database, including processing a backfile of more than 20 years of patents. "Within this project, the TEMIS Insight Discoverer(tm) Extractor engine was used to derive semantic relations from chemical patents," said Dr. W. Douglas Hounshell, Vice President of Content Development at Elsevier MDL. "The combination of TEMIS proficiency in linguistic analysis with Elsevier MDL expertise in chemistry has contributed to the success of MDL® Patent Chemistry Database, launched in 2004."

"The collaboration between Elsevier MDL and TEMIS has already paid off on the production side, and I am very happy that we are now joining forces to bring out a software tool that has been requested by our core customers for some time. Combining Elsevier MDL's expertise in chemical informatics with TEMIS' skills in the text mining area has produced an indispensable chemical information extraction solution" said Dr. Michiel Kolman, Managing Director, MDL Information Systems GmbH. 

The new Chemical Entity Relationship Skill Cartridge(tm) greatly extends the TEMIS Skill Cartridge(tm) Library, which already includes cartridges such as the Biological Entity Relationship Skill Cartridge(tm) and the Medical Entity Relationship Skill Cartridge(tm), and thus adds a strategic element to the TEMIS Life Sciences portfolio. Through its Skill Cartridge(tm) Library, TEMIS supports scientific research projects by addressing issues such as drug-target interactions and drug-drug interactions for safety assessment. The TEMIS information discovery solution, Online Miner(tm), also leverages the Chemical Entity Relationship Skill Cartridge(tm) within its Intellectual Property application (IP-Miner).

"We are very proud that the successful partnership between Elsevier MDL and TEMIS has resulted in this first joint product development," said Dr. Günther Kurapkat, Director Life Sciences, TEMIS. "The new Chemical Entity Relationship Skill Cartridge(tm) for mining chemical documents offers unique functionality and quality to the market and adds another strategic product to the TEMIS Life Science portfolio, enabling us to provide our customer base with cutting-edge technology developed by the two market leaders in chemistry and text-mining." Under the terms of the agreement, TEMIS is the exclusive channel of the Chemical Entity Relationship Skill Cartridge(tm).

About Elsevier MDL 
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists' decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com.

Elsevier is a world-leading publisher of scientific, technical and medical information products and services.

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.

About TEMIS
TEMIS develops and markets software solutions for Text Mining, which optimize the use of information by extracting documents' key concepts and their meanings, for automatic classification and the discovery of new factual relationships and associations. TEMIS products play a critical role in fields where information processing is complex due to the great volume of data, such as Competitive Intelligence, Customer Relationship Management, Scientific Intelligence and Human Resources, and these products provide substantial productivity gains. TEMIS software provides superior results from Text Mining, due to its advanced linguistic engine and the use of customizable, domain-specific Skill Cartridges(tm).

The company was created in September 2000 and currently has subsidiaries or offices in France, Germany, the United Kingdom, Italy, and the United States, and partners throughout the world. From the very start, TEMIS' innovative technology has attracted major corporations (Bertelsmann, EADS CRC, Alcatel, France Télécom, TIM-Telecom Italia Mobile, EDF, Documentum, IBM, IPSEN, LION bioscience, Elsevier MDL, Novartis, DaimlerChrysler, PSA Peugeot-Citroën, Renault, Total, etc.)

TEMIS has gained the trust of major financial partners, with Crédit Agricole Private Equity and ACE Management owning shares in the company. In July 2003, TEMIS acquired Xerox Corporation's linguistic product operation, consisting of a team of 9 people and both XeLDA® and XTS software products. www.temis.com

For further information, please contact:

TEMIS Media Contact: 
Martine Falhon  
Corporate Communications 
+33 (0)4 56 38 24 03 
martine.falhon@temis-group.com

Guenther Kurapkat
Director Life Sciences
+49 6221 13753-13
guenther.kurapkat@temis-group.com

Elsevier MDL 
Dr. Phil McHale 
Corporate Communications 
(510) 357-2222 ext. 3541 
p.mchale@mdl.com  

MDL is a registered trademark of MDL Information Systems, Inc. ('Elsevier MDL') in the United States. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).